Cancer Treatment Reviews
Издатель: Elsevier · ISSN 0305-7372 · 33 статей
- Co-targeting VEGF and PD-(L)1 in gastrointestinal cancers: biology, clinical landscape, and therapeutic frontiers
- Tissue and blood-based biomarkers of immunotherapy response in head and neck Cancer
- Immune checkpoint inhibitor resistance in gastric and colorectal cancers
- The evolving landscape of DLL3-directed Therapeutics in small cell lung cancer
- Editorial Board
- MTAP loss in non–small-cell lung Cancer and beyond: Therapeutic targeting of the MAT2A–PRMT5 axis
- Molecular tumor boards implementation in Europe: a scoping review and thematic analysis of challenges and facilitators
- Bispecific antibodies in lung cancer: From molecular engineering to clinical breakthroughs and translational challenges
- p53 Co-mutations in EGFR-mutant NSCLC: biological insight and therapeutic implications
- Reduced oxaliplatin exposure in gastrointestinal cancers: A systematic review and meta-analysis
- Optimizing the treatment pathway in post-docetaxel mCRPC: PSMA-RLT vs cabazitaxel
- “Current approaches and emerging strategies in the treatment of ductal carcinoma in situ and premalignant breast lesions”
- From drug response to resistance evolution: Leveraging 3D cancer models for functional precision oncology
- Advancing therapies for HER2-positive metastatic breast cancer: Navigating a wealth of treatment options
- Selective estrogen receptor degraders in premenopausal breast cancer: Biological activity and endpoint relevance in window of opportunity trials
- Artificial intelligence–enabled drug discovery: A growing but largely early-stage clinical pipeline
- CDH1 germline carriers and diffuse gastric Cancer: Are we ready for personalized surveillance and prevention?
- Role of maintaining the TKI backbone in oncogene-driven NSCLC after progression
- Managing the renal primary in metastatic clear-cell RCC in the IO–TKI era: a systemic-first, response-adapted strategy
- Systemic therapy for metastatic nasopharyngeal carcinoma in the immunotherapy era: A critical review
- Immune checkpoint inhibitors in platinum-resistant ovarian cancer: Clinical disappointments, biological lessons, and the reopening of therapeutic opportunities
- T-cell engagers in small-cell lung cancer: current evidence and future directions – a position statement from the ETOP IBCSG Partners Foundation Workshop
- Local and systemic inflammatory and immune pathways in anaplastic thyroid carcinoma: emerging therapeutic targets
- PARP inhibitors in breast cancer: From DNA repair targeting to next-generation precision therapeutics
- Deep and ultra-deep PSA responses as prognostic biomarkers in metastatic hormone-sensitive prostate cancer. A systematic review and implications for treatment personalization
- The arrival of subcutaneous antineoplastic cancer therapies
- Targeted protein degradation as next-generation therapeutic modality for childhood cancer
- Recognition and management of organ-specific toxicities associated with enfortumab vedotin plus pembrolizumab and erdafitinib in locally advanced or metastatic urothelial carcinoma
- Incidence and severity of nausea and vomiting with trastuzumab deruxtecan: a systematic review and meta-analysis
- Exercise as anticancer medicine? Evidence, mechanisms and implementation in oncology